Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of Neurology, The First Hospital of Tsinghua University, Beijing, China.
Parkinsonism Relat Disord. 2022 Oct;103:92-97. doi: 10.1016/j.parkreldis.2022.08.022. Epub 2022 Sep 5.
INTRODUCTION: Constipation is one of the common non-motor symptoms in Parkinson's disease that significantly impacts patient quality of life. Probiotics supplementation may improve constipation symptoms, but its effect on the gut microbiota population is unclear. METHODS: In this randomized controlled study, 46 PD patients with constipation according to Rome Ⅲ criteria were recruited. The number of complete bowel movements per week, degree of defecation effort, Bristol stool Scale (BSS), Patient Assessment of Constipation symptom (PAC-SYM) and Patient assessment of constipation quality of life questionnaire (PAC-QOL) were collected pre- and post-intervention to evaluate the constipation symptoms. In addition, fresh feces of subjects before and after intervention and healthy controls were collected for 16s rRNA gene V3-V4 region sequencing to compare bacterial flora differences. RESULTS: Compared with the control group, the treatment group increased the average number of complete bowel movements per week (1.09 ± 1.24 vs. 0.04 ± 0.64, P < 0.001). Probiotics supplementation reduced the BSS score (0.65 ± 0.93 vs. -0.17 ± 0.94, P = 0.004), PAC-SYM score (4.09 ± 6.31 vs. -1.83 ± 4.14, P < 0.001), PAC-QOL score (10.65 ± 16.53 vs. 0.57 ± 12.82, P = 0.042), and degree of defecation effort score (1.00 ± 0.80 vs. 0.00 ± 0.30, P < 0.001). The improvement rate of constipation in the probiotics group was significantly higher than that in the control group (52.2% vs. 8.7%, P = 0.001). PD patients showed intestinal flora disorders compared to healthy controls. After 12 weeks of probiotics treatment, g_Christensenella_sp._Marseille-P2437 significantly increased, while g_Eubacterium_oxidoreducens_group, g_Eubacterium_hallii_group and s_Odoribacter_sp._N54.MGS-14 decreased (p < 0 0.05). CONCLUSIONS: Probiotics treatment can effectively improve the constipation symptoms of PD patients and positively affected the gut microbiota.
简介:便秘是帕金森病常见的非运动症状之一,严重影响患者的生活质量。益生菌补充剂可能改善便秘症状,但对肠道微生物群的影响尚不清楚。
方法:本随机对照研究纳入了 46 例符合罗马 III 标准的帕金森病便秘患者。采用每周完全排便次数、排便费力程度、布里斯托大便形状量表(Bristol stool Scale,BSS)、便秘患者症状评估(Patient Assessment of Constipation symptom,PAC-SYM)和便秘患者生活质量问卷(Patient assessment of constipation quality of life questionnaire,PAC-QOL)评估便秘症状。此外,在干预前后采集受试者新鲜粪便和健康对照者的粪便进行 16s rRNA 基因 V3-V4 区测序,比较细菌菌群差异。
结果:与对照组相比,治疗组每周完全排便次数增加(1.09±1.24 比 0.04±0.64,P<0.001)。益生菌补充剂降低了 BSS 评分(0.65±0.93 比-0.17±0.94,P=0.004)、PAC-SYM 评分(4.09±6.31 比-1.83±4.14,P<0.001)、PAC-QOL 评分(10.65±16.53 比 0.57±12.82,P=0.042)和排便费力程度评分(1.00±0.80 比 0.00±0.30,P<0.001)。益生菌组便秘改善率明显高于对照组(52.2%比 8.7%,P=0.001)。与健康对照组相比,PD 患者表现出肠道菌群失调。经过 12 周的益生菌治疗后,g_Christensenella_sp._Marseille-P2437 显著增加,而 g_Eubacterium_oxidoreducens_group、g_Eubacterium_hallii_group 和 s_Odoribacter_sp._N54.MGS-14 减少(p<0.05)。
结论:益生菌治疗可有效改善 PD 患者的便秘症状,并对肠道微生物群产生积极影响。
Parkinsonism Relat Disord. 2022-10
Zhonghua Wei Chang Wai Ke Za Zhi. 2016-12-25
Microb Cell Fact. 2021-5-13
Complement Ther Med. 2024-6
Front Cell Infect Microbiol. 2022
J Cent Nerv Syst Dis. 2025-8-13
Biomedicines. 2025-5-31
Mov Disord Clin Pract. 2025-3-13